These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 20587403)

  • 1. Novel treatment approaches for triple-negative breast cancer.
    Telli ML; Ford JM
    Clin Breast Cancer; 2010; 10 Suppl 1():E16-22. PubMed ID: 20587403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The triple-negative subtype: new ideas for the poorest prognosis breast cancer.
    Curigliano G; Goldhirsch A
    J Natl Cancer Inst Monogr; 2011; 2011(43):108-10. PubMed ID: 22043054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple-negative breast cancer: current state of the art.
    Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
    Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple-negative breast cancer.
    Bartsch R; Ziebermayr R; Zielinski CC; Steger GG
    Wien Med Wochenschr; 2010 Apr; 160(7-8):174-81. PubMed ID: 20473728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Targeting" triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers.
    Nanda R
    Semin Oncol; 2011 Apr; 38(2):254-62. PubMed ID: 21421115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic options for triple-negative breast cancers with defective homologous recombination.
    Jaspers JE; Rottenberg S; Jonkers J
    Biochim Biophys Acta; 2009 Dec; 1796(2):266-80. PubMed ID: 19616605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple-negative breast cancer: advancements in characterization and treatment approach.
    Hurvitz S; Mead M
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple-negative breast cancer and poly(ADP-ribose) polymerase inhibitors.
    Park Y; Moriyama A; Kitahara T; Yoshida Y; Urita T; Kato R
    Anticancer Agents Med Chem; 2012 Jul; 12(6):672-7. PubMed ID: 22263793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of triple-negative breast cancer.
    de Ruijter TC; Veeck J; de Hoon JP; van Engeland M; Tjan-Heijnen VC
    J Cancer Res Clin Oncol; 2011 Feb; 137(2):183-92. PubMed ID: 21069385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapy for triple-negative breast cancer: where are we?
    Duffy MJ; McGowan PM; Crown J
    Int J Cancer; 2012 Dec; 131(11):2471-7. PubMed ID: 22581656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triple-negative breast cancer: disease entity or title of convenience?
    Carey L; Winer E; Viale G; Cameron D; Gianni L
    Nat Rev Clin Oncol; 2010 Dec; 7(12):683-92. PubMed ID: 20877296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Directed therapy of subtypes of triple-negative breast cancer.
    Carey LA
    Oncologist; 2011; 16 Suppl 1():71-8. PubMed ID: 21278443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Directed therapy of subtypes of triple-negative breast cancer.
    Carey LA
    Oncologist; 2010; 15 Suppl 5():49-56. PubMed ID: 21138955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular stratification of triple-negative breast cancers.
    Perou CM
    Oncologist; 2010; 15 Suppl 5():39-48. PubMed ID: 21138954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissecting the heterogeneity of triple-negative breast cancer.
    Metzger-Filho O; Tutt A; de Azambuja E; Saini KS; Viale G; Loi S; Bradbury I; Bliss JM; Azim HA; Ellis P; Di Leo A; Baselga J; Sotiriou C; Piccart-Gebhart M
    J Clin Oncol; 2012 May; 30(15):1879-87. PubMed ID: 22454417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [PARP inhibitors and their role in the therapy of triple-negative metastatic breast cancer].
    Kozioł M; Püsküllüoglu M; Zygulska A
    Przegl Lek; 2012; 69(6):265-70. PubMed ID: 23094440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular stratification of triple-negative breast cancers.
    Perou CM
    Oncologist; 2011; 16 Suppl 1():61-70. PubMed ID: 21278442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The emerging potential of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer.
    Drew Y; Plummer R
    Curr Opin Obstet Gynecol; 2010 Feb; 22(1):67-71. PubMed ID: 19934756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition.
    Shibata H; Miuma S; Saldivar JC; Huebner K
    Cancer Sci; 2011 Oct; 102(10):1882-8. PubMed ID: 21707865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple negative breast cancer: a brief review of its characteristics and treatment options.
    Griffiths CL; Olin JL
    J Pharm Pract; 2012 Jun; 25(3):319-23. PubMed ID: 22551559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.